Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 396

1.

The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection.

Trøseid M, Mayerhofer CCK, Broch K, Arora S, Svardal A, Hov JR, Andreassen AK, Gude E, Karason K, Dellgren G, Berge RK, Gullestad L, Aukrust P, Ueland T.

J Heart Lung Transplant. 2019 Jun 19. pii: S1053-2498(19)31545-1. doi: 10.1016/j.healun.2019.06.003. [Epub ahead of print]

PMID:
31301965
2.

The Predictive Value of Depression in the Years After Heart Transplantation for Mortality During Long-Term Follow-Up.

Bürker BS, Gullestad L, Gude E, Havik OE, Relbo Authen A, Grov I, Andreassen AK, Fiane AE, Haraldsen IR, Dew MA, Andersson S, Malt UF.

Psychosom Med. 2019 Jul/Aug;81(6):513-520. doi: 10.1097/PSY.0000000000000702.

PMID:
31033937
3.

Statin-associated muscle symptoms in coronary patients: design of a randomized study.

Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E.

Scand Cardiovasc J. 2019 Jun;53(3):162-168. doi: 10.1080/14017431.2019.1612085. Epub 2019 May 13.

PMID:
31030568
4.

Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.

Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L; SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) investigators.

Transplantation. 2019 Mar 12. doi: 10.1097/TP.0000000000002702. [Epub ahead of print]

PMID:
30893292
5.

Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation.

Arora S, Ofstad AP, Ulimoen GR, Birkeland KI, Endresen K, Gullestad L, Johansen OE.

Cardiovasc Diabetol. 2019 Mar 9;18(1):26. doi: 10.1186/s12933-019-0832-2.

6.

Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study.

Solberg OG, Stavem K, Ragnarsson A, Beitnes JO, Skårdal R, Seljeflot I, Ueland T, Aukrust P, Gullestad L, Aaberge L.

Catheter Cardiovasc Interv. 2019 Feb 21. doi: 10.1002/ccd.28157. [Epub ahead of print]

PMID:
30790446
7.

Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia.

Nytrøen K, Rolid K, Andreassen AK, Yardley M, Gude E, Dahle DO, Bjørkelund E, Relbo Authen A, Grov I, Philip Wigh J, Have Dall C, Gustafsson F, Karason K, Gullestad L.

Circulation. 2019 May 7;139(19):2198-2211. doi: 10.1161/CIRCULATIONAHA.118.036747.

PMID:
30773030
8.

Medical and Psychosocial Factors Associated With Low Physical Activity and Increasing Exercise Level After a Coronary Event.

Peersen K, Otterstad JE, Sverre E, Perk J, Gullestad L, Moum T, Dammen T, Munkhaugen J.

J Cardiopulm Rehabil Prev. 2019 Jan 31. doi: 10.1097/HCR.0000000000000399. [Epub ahead of print]

PMID:
30720643
9.

Treatment of sleep apnea in patients with paroxysmal atrial fibrillation: design and rationale of a randomized controlled trial.

Traaen GM, Aakerøy L, Hunt TE, Øverland B, Lyseggen E, Aukrust P, Ueland T, Helle-Valle T, Steinshamn S, Edvardsen T, Khiabani Zaré H, Aakhus S, Akre H, Anfinsen OG, Loennechen JP, Gullestad L.

Scand Cardiovasc J. 2018 Dec;52(6):372-377. doi: 10.1080/14017431.2019.1567933. Epub 2019 Feb 5.

PMID:
30638392
10.

Prevalence and prognostic implication of iron deficiency and anaemia in patients with severe aortic stenosis.

Kvaslerud AB, Hussain AI, Auensen A, Ueland T, Michelsen AE, Pettersen KI, Aukrust P, Mørkrid L, Gullestad L, Broch K.

Open Heart. 2018 Dec 16;5(2):e000901. doi: 10.1136/openhrt-2018-000901. eCollection 2018.

11.

Espeland and co-workers respond.

Espeland T, Lunde IG, Amundsen BH, Gullestad L, Aakhus S.

Tidsskr Nor Laegeforen. 2018 Nov 26;138(19). doi: 10.4045/tidsskr.18.0865. Print 2018 Nov 27. Norwegian. No abstract available.

12.

sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.

Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Gullestad L, Broch K, Ueland T, Nymo SH, Brunner-La Rocca HP, de Boer RA, Gaggin HK, Ripoli A, Passino C, Januzzi JL Jr.

J Am Coll Cardiol. 2018 Nov 6;72(19):2309-2320. doi: 10.1016/j.jacc.2018.08.2165.

PMID:
30384887
13.

Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.

Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L; SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators.

Circ Heart Fail. 2018 Sep;11(9):e004050. doi: 10.1161/CIRCHEARTFAILURE.117.004050.

PMID:
30354362
14.

Myocardial fibrosis.

Espeland T, Lunde IG, H Amundsen B, Gullestad L, Aakhus S.

Tidsskr Nor Laegeforen. 2018 Oct 12;138(16). doi: 10.4045/tidsskr.17.1027. Print 2018 Oct 16. Review. English, Norwegian.

15.

Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression.

Norum HM, Michelsen AE, Lekva T, Arora S, Otterdal K, Olsen MB, Kong XY, Gude E, Andreassen AK, Solbu D, Karason K, Dellgren G, Gullestad L, Aukrust P, Ueland T.

Am J Transplant. 2019 Apr;19(4):1050-1060. doi: 10.1111/ajt.15141. Epub 2018 Nov 5.

PMID:
30312541
16.

Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction.

Ueland T, Kleveland O, Michelsen AE, Wiseth R, Damås JK, Aukrust P, Gullestad L, Halvorsen B, Yndestad A.

Open Heart. 2018 Sep 18;5(2):e000765. doi: 10.1136/openhrt-2017-000765. eCollection 2018.

17.

IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.

Orrem HL, Nilsson PH, Pischke SE, Kleveland O, Yndestad A, Ekholt K, Damås JK, Espevik T, Bendz B, Halvorsen B, Gregersen I, Wiseth R, Andersen GØ, Ueland T, Gullestad L, Aukrust P, Barratt-Due A, Mollnes TE.

Front Immunol. 2018 Sep 12;9:2035. doi: 10.3389/fimmu.2018.02035. eCollection 2018.

18.

Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial.

Andreassen AK, Broch K, Eiskjær H, Karason K, Gude E, Mølbak D, Stueflotten W, Gullestad L; SCHEDULE (SCandinavian HEart transplant everolimus De-novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators.

Transplantation. 2019 Apr;103(4):781-788. doi: 10.1097/TP.0000000000002445.

PMID:
30211826
19.

Clinical features and determinants of VO2peak in de novo heart transplant recipients.

Rolid K, Andreassen AK, Yardley M, Bjørkelund E, Karason K, Wigh JP, Dall CH, Gustafsson F, Gullestad L, Nytrøen K.

World J Transplant. 2018 Sep 10;8(5):188-197. doi: 10.5500/wjt.v8.i5.188.

20.

Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.

Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N.

ESC Heart Fail. 2018 Dec;5(6):1052-1059. doi: 10.1002/ehf2.12312. Epub 2018 Aug 25.

21.

Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial.

Mayerhofer CCK, Awoyemi AO, Moscavitch SD, Lappegård KT, Hov JR, Aukrust P, Hovland A, Lorenzo A, Halvorsen S, Seljeflot I, Gullestad L, Trøseid M, Broch K.

ESC Heart Fail. 2018 Oct;5(5):977-984. doi: 10.1002/ehf2.12332. Epub 2018 Aug 7. Review.

22.

Managing patients with prediabetes and type 2 diabetes after coronary events: individual tailoring needed - a cross-sectional study.

Munkhaugen J, Hjelmesæth J, Otterstad JE, Helseth R, Sollid ST, Gjertsen E, Gullestad L, Perk J, Moum T, Husebye E, Dammen T.

BMC Cardiovasc Disord. 2018 Aug 3;18(1):160. doi: 10.1186/s12872-018-0896-z.

23.

T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF.

Abraityte A, Aukrust P, Kou L, Anand IS, Young J, Mcmurray JJV, van Veldhuisen DJ, Gullestad L, Ueland T.

Clin Res Cardiol. 2019 Feb;108(2):133-141. doi: 10.1007/s00392-018-1331-2. Epub 2018 Jul 26.

PMID:
30051179
24.

Author's response to: letter to the editor.

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE.

Heart Fail Rev. 2018 Sep;23(5):819. doi: 10.1007/s10741-018-9728-6. No abstract available.

PMID:
30043131
25.

High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes.

Heier M, Ofstad AP, Borja MS, Brunborg C, Endresen K, Gullestad L, Birkeland KI, Johansen OE, Oda MN.

Atherosclerosis. 2019 Mar;282:183-187. doi: 10.1016/j.atherosclerosis.2018.07.005. Epub 2018 Jul 6.

26.

Response to the editor.

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE.

Heart Fail Rev. 2018 Jul 2. doi: 10.1007/s10741-018-9723-y. [Epub ahead of print] No abstract available.

PMID:
29968222
27.

Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction.

Ueland T, Kleveland O, Michelsen AE, Wiseth R, Damås JK, Holven KB, Aukrust P, Gullestad L, Yndestad A, Halvorsen B.

Int J Cardiol. 2019 Jan 1;274:348-350. doi: 10.1016/j.ijcard.2018.06.093. Epub 2018 Jun 27.

PMID:
29961573
28.

Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction.

Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K, Holte E, Ryan L, Amundsen BH, Bendz B, Aakhus S, Espevik T, Halvorsen B, Mollnes TE, Wiseth R, Gullestad L, Aukrust P, Damås JK.

Int J Cardiol. 2018 Nov 15;271:1-7. doi: 10.1016/j.ijcard.2018.04.136. Epub 2018 Jun 29.

PMID:
29961572
29.

Age-dependent morbidity and mortality outcomes after surgical aortic valve replacement.

Hussain AI, Auensen A, Brunborg C, Beitnes JO, Gullestad L, Pettersen KI.

Interact Cardiovasc Thorac Surg. 2018 Nov 1;27(5):650-656. doi: 10.1093/icvts/ivy154.

PMID:
29746650
30.

The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event.

Munkhaugen J, Otterstad JE, Dammen T, Gjertsen E, Moum T, Husebye E, Gullestad L.

Eur J Prev Cardiol. 2018 Jun;25(9):923-931. doi: 10.1177/2047487318768940. Epub 2018 Apr 11.

PMID:
29635941
31.

The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE.

Heart Fail Rev. 2018 May;23(3):303-323. doi: 10.1007/s10741-018-9685-0. Review.

32.

The follow-up after myocardial infarction - is it good enough?

Munkhaugen J, Peersen K, Sverre E, Gjertsen E, Gullestad L, Dammen T, Husebye E, Otterstad JE.

Tidsskr Nor Laegeforen. 2018 Mar 5;138(5). doi: 10.4045/tidsskr.17.1050. Print 2018 Mar 6. English, Norwegian. No abstract available.

33.

Importance of physical capacity and the effects of exercise in heart transplant recipients.

Yardley M, Gullestad L, Nytrøen K.

World J Transplant. 2018 Feb 24;8(1):1-12. doi: 10.5500/wjt.v8.i1.1. Review.

34.

Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.

Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN, Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS, Kjekshus J, Køber L, Lepore V, Lucisano G, Maggioni AP, Masson S, McMurray JJV, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R, Tognoni G, Wikstrand J, Latini R.

Eur J Heart Fail. 2018 May;20(5):888-895. doi: 10.1002/ejhf.1146. Epub 2018 Feb 28.

35.

Determinants and Outcome of Decision Making Among Patients with Severe Aortic Stenosis.

Hussain AI, Auensen A, Brunborg C, Aakhus S, Fiane A, Pettersen KI, Gullestad L.

J Heart Valve Dis. 2017 Jul;26(4):413-422.

PMID:
29302940
36.

Immediate response in markers of inflammation and angiogenesis during exercise: a randomised cross-over study in heart transplant recipients.

Yardley M, Ueland T, Aukrust P, Michelsen A, Bjørkelund E, Gullestad L, Nytrøen K.

Open Heart. 2017 Nov 28;4(2):e000635. doi: 10.1136/openhrt-2017-000635. eCollection 2017.

37.

Optimal blood pressure control after coronary events: the challenge remains.

Sverre E, Peersen K, Otterstad JE, Gullestad L, Perk J, Gjertsen E, Moum T, Husebye E, Dammen T, Munkhaugen J.

J Am Soc Hypertens. 2017 Dec;11(12):823-830. doi: 10.1016/j.jash.2017.10.007. Epub 2017 Oct 28.

PMID:
29128603
38.

Cognitive function among long-term survivors of heart transplantation.

Bürker BS, Gude E, Gullestad L, Grov I, Relbo Authen A, Andreassen AK, Havik OE, Dew MA, Fiane AE, Haraldsen IR, Malt UF, Andersson S.

Clin Transplant. 2017 Dec;31(12). doi: 10.1111/ctr.13143. Epub 2017 Nov 15.

PMID:
29055147
39.

Health-related quality of life in older patients with acute coronary syndrome randomised to an invasive or conservative strategy. The After Eighty randomised controlled trial.

Tegn N, Abdelnoor M, Aaberge L, Hylen Ranhoff A, Endresen K, Gjertsen E, Skårdal R, Gullestad L, Bendz B; After Eighty study investigators.

Age Ageing. 2018 Jan 1;47(1):42-47. doi: 10.1093/ageing/afx121.

PMID:
28985265
40.

Patient-reported outcomes after referral for possible valve replacement in patients with severe aortic stenosis.

Auensen A, Hussain AI, Garratt AM, Gullestad LL, Pettersen KI.

Eur J Cardiothorac Surg. 2018 Jan 1;53(1):129-135. doi: 10.1093/ejcts/ezx228.

PMID:
28977361
41.

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.

Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP, Desai AS, Solomon SD, Pfeffer MA, Cheng S, Gullestad L, Aukrust P, Ueland T, Swedberg K, Young JB, Kattan MW, Sattar N, McMurray JJV.

Eur J Heart Fail. 2018 Feb;20(2):268-277. doi: 10.1002/ejhf.988. Epub 2017 Sep 27.

42.

Medical and sociodemographic factors predict persistent smoking after coronary events.

Sverre E, Otterstad JE, Gjertsen E, Gullestad L, Husebye E, Dammen T, Moum T, Munkhaugen J.

BMC Cardiovasc Disord. 2017 Sep 6;17(1):241. doi: 10.1186/s12872-017-0676-1.

43.

The predictive value of coronary artery calcium detected by computed tomography in a prospective study on cardiac allograft vasculopathy in heart transplant patients.

Günther A, Andersen R, Gude E, Jakobsen J, Edvardsen T, Sandvik L, Abildgaard A, Aaberge L, Gullestad L.

Transpl Int. 2018 Jan;31(1):82-91. doi: 10.1111/tri.13057. Epub 2017 Sep 21.

44.

Increased Secondary/Primary Bile Acid Ratio in Chronic Heart Failure.

Mayerhofer CCK, Ueland T, Broch K, Vincent RP, Cross GF, Dahl CP, Aukrust P, Gullestad L, Hov JR, Trøseid M.

J Card Fail. 2017 Sep;23(9):666-671. doi: 10.1016/j.cardfail.2017.06.007. Epub 2017 Jul 5.

PMID:
28688889
45.

Morbidity outcomes after surgical aortic valve replacement.

Auensen A, Hussain AI, Bendz B, Aaberge L, Falk RS, Walle-Hansen MM, Bye J, Andreassen J, Beitnes JO, Rein KA, Pettersen KI, Gullestad L.

Open Heart. 2017 Apr 13;4(1):e000588. doi: 10.1136/openhrt-2017-000588. eCollection 2017.

46.

The role of cardiac rehabilitation in secondary prevention after coronary events.

Peersen K, Munkhaugen J, Gullestad L, Liodden T, Moum T, Dammen T, Perk J, Otterstad JE.

Eur J Prev Cardiol. 2017 Sep;24(13):1360-1368. doi: 10.1177/2047487317719355. Epub 2017 Jun 30.

PMID:
28664773
47.

Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE).

Relbo Authen A, Grov I, Karason K, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Dellgren G, Solbu D, Arora S, Andreassen AK, Gullestad L.

Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13038. Epub 2017 Jul 19.

PMID:
28640529
48.

Long-term follow-up of a hospital-based, multi-intervention programme in type 2 diabetes mellitus: impact on cardiovascular events and death.

Ofstad AP, Ulimoen GR, Orvik E, Birkeland KI, Gullestad LL, Fagerland MW, Johansen OE.

J Int Med Res. 2017 Oct;45(5):1535-1552. doi: 10.1177/0300060517707674. Epub 2017 Jun 19.

49.

Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy.

Abraityte A, Lunde IG, Askevold ET, Michelsen AE, Christensen G, Aukrust P, Yndestad A, Fiane A, Andreassen A, Aakhus S, Dahl CP, Gullestad L, Broch K, Ueland T.

Sci Rep. 2017 Jun 14;7(1):3490. doi: 10.1038/s41598-017-03625-9.

50.

Associations of brain-natriuretic peptide, high-sensitive troponin T, and high-sensitive C-reactive protein with outcomes in severe aortic stenosis.

Auensen A, Hussain AI, Falk RS, Walle-Hansen MM, Bye J, Pettersen KI, Aukrust P, Ueland T, Gullestad LL.

PLoS One. 2017 Jun 12;12(6):e0179304. doi: 10.1371/journal.pone.0179304. eCollection 2017.

Supplemental Content

Loading ...
Support Center